Remove 2025 Remove Stenosis Remove TAVR
article thumbnail

TAVR System Shows Durable Clinical Outcomes, Strong Valve Performance in Low-Risk Aortic Stenosis Patients

DAIC

tim.hodson Mon, 03/31/2025 - 15:39 March 30, 2025 Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. The Evolut Low Risk Trial was a randomized, multicenter, international study assessing the safety and efficacy of the Evolut TAVR system versus surgery in low-risk patients.

TAVR 52
article thumbnail

SCAI Scientific Sessions 2025 to Feature Presentations on TAVR, PAD and PE 

DAIC

tim.hodson Fri, 03/14/2025 - 16:12 SCAI Scientific Sessions 2025 will take place May 1 to 3, attheWalter E. Washington Convention Center in Washington, DC.

TAVR 52
article thumbnail

Edwards Acquires JenaValve and Endotronix, Expands into Aortic Regurgitation and Heart Failure

CardiacWire

These two acquisitions could impact Edwards’ structural heart and heart failure portfolios in unique and meaningful ways… JenaValve’s Trilogy TAVR system doesn’t yet have FDA approval, but is CE Marked for both aortic regurgitation and aortic stenosis, which is notable given that all other TAVR systems only address aortic stenosis.

article thumbnail

Impact of Age on Aortic Valve Replacement Choices in Low-Risk Patients

Society of Thoracic Surgeons - Congenital

At STS 2025, Dr. Tomaz Mesar presented a study comparing outcomes of TAVR and SAVR in low-risk patients with aortic stenosis.

article thumbnail

Abstract TP316: Stroke Events in Cancer Versus Non-Cancer Patients With Aortic Stenosis During Transcatheter Aortic Valve Replacement

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page ATP316-ATP316, February 1, 2025. Background:Despite improvements in the safety of transcatheter aortic valve replacement (TAVR), ~4% of patients experience a procedure-related stroke. Patients were stratified into two groups: cancer patients 13583 (96.7%) and non-cancer patients 463 (3.3%).

article thumbnail

Latin Heart Rounds Series: Current Management of Bicuspid Aortic Valve—Lifetime Management of Aortic Stenosis

Society of Thoracic Surgeons - Congenital

Presenters will explain internationally accepted nomenclature and classification by its main developer, as well as comment on the pros and cons and short and mid/long-term outcomes of SAVR and TAVR in this challenging population.